NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024

NewAmsterdam Pharma Co N.V.

2024-Q1 EPS reported -$1.06 revenue$1,401,000

Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.
Cash position $481.1M at March 31, vs $340.5M Dec 31, bolstered by $190M public offering.
Net loss $93.8M ($1.06/diluted share) vs $42.0M ($0.51) year ago; revenue fell to $1.4M from $8.6M.
Dosed first patients in TANDEM (fixed-dose obicetrapib/ezetimibe); topline expected Q1 2025.
Appointed William H. Lewis as Board Chair and Juliette Audet as Chief Business Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NewAmsterdam Pharma Co N.V. reported financial results for quarter ended March 31, 2024.

Period: quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0000950170-24-056292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.